Compare LWLG & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LWLG | ANNX |
|---|---|---|
| Founded | 1991 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 625.9M | 726.1M |
| IPO Year | 2011 | 2020 |
| Metric | LWLG | ANNX |
|---|---|---|
| Price | $4.14 | $3.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | $9.00 | ★ $17.00 |
| AVG Volume (30 Days) | 3.4M | ★ 3.4M |
| Earning Date | 11-13-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.79 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $236,855.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $998.56 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 147.74 | N/A |
| 52 Week Low | $2.84 | $2.54 |
| 52 Week High | $18.71 | $7.18 |
| Indicator | LWLG | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 39.41 | 41.32 |
| Support Level | $3.80 | $3.36 |
| Resistance Level | $5.73 | $4.37 |
| Average True Range (ATR) | 0.35 | 0.24 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 22.19 | 40.85 |
Lightwave Logic Inc is a specialty materials and intellectual property company focused on the development and commercialization of proprietary electro-optic (EO) polymer materials designed to enable high-speed optical modulators for data communications and other photonic applications. Its Perkinamine family of EO polymers is designed for integration into silicon photonics (SiPh) and other photonic integrated circuit (PIC) platforms, supporting high-speed optical modulation with lower drive voltage requirements compared with some conventional silicon-based and III-V compound semiconductor approaches. The company operates as a single reportable segment.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.